Nvidia earnings without Huang
Posters frame Tuesday's Nvidia report, the first in 33 years without Huang on the call, as a test of guidance and customer commitment after a sharp selloff.
Nov 13, 23:00 - Nov 15, 23:00 Lisbon
Post-Market AlphaReddit weighed Nvidia's first earnings call without Huang and its investments in chip buyers, while r/Semiconductors flagged Advantest pulling forward its 10,000-tester target.
Posters frame Tuesday's Nvidia report, the first in 33 years without Huang on the call, as a test of guidance and customer commitment after a sharp selloff.
One poster asks whether Nvidia funding AI startups to absorb excess TSMC silicon is a bubble signal; a separate post says only 41% of its $63 billion in stakes were in chip buyers and that its biggest stake is Intel.
The post links the target to rising per-chip test time from chip complexity rather than higher chip volumes, and asks what may be missing.
Advantest just moved its 10,000-tester target forward a year. What am I missing?
On that reading, tester demand can grow without higher chip volumes.
Watch Advantest's progress toward 10,000 testers.
Open originalThe author has AI exposure through NVDA and AVGO and warns that if prepayments for contracts are cancelled, Oracle and CoreWeave might have issues paying their debts.
Rising CDS spreads for the AI buildout Are rising CDS spreads signalling trouble ahead for the market?
The author sees rising CDS spreads as a credit-risk signal for Oracle and CoreWeave.
Watch Oracle and CoreWeave CDS spreads.
Open originalThe poster cites the FT figure as a sign that the AI infrastructure trade is cracking.
The AI infrastructure trade is cracking. Per the FT, manufacturing, utility and mining stocks have lost $4.2T since June.
The poster reads the losses in these sectors as the AI infrastructure trade cracking.
Watch Whether AI infrastructure-linked industrial and utility stocks stabilize.
Open originalThe author cites a 66% nausea rate and a 32% vomiting rate at the 1.7mg/1.7mg dose and calls Novo Nordisk a value trap with a weak pipeline.
Obesity Week 2026: Novo's CagriSema 1.7mg/1.7mg shows LESS weight loss than 1.0mg/1.0mg with 66% nausea rate & 32% vomit rate
Dose response and GI tolerability are the author's case against Novo's obesity pipeline.
Watch Further CagriSema trial data.
Open originalThe post reports the rejection of the PD-1 x VEGF drug's BLA and links it to the firing of its commercial leadership.
Summit’s ivonescimab (PD-1 x VEGF) BLA rejected by the FDA Explains why they fired their whole commercial leadership last week…
The post says the rejection explains why Summit fired its commercial leadership last week.
Watch Summit's response to the FDA decision.
Open originalThe author remains bullish, citing the company's broadening business segments and scale economies.
Wise H1 FY27 Earnings Release \*\* Disclosure - I am a shareholder in Wise \*\* Wise is often cited as
The author estimates rising customer acquisition costs but sees the business broadening.
Watch Wise's personal volume growth and acquisition costs in the next update.
Open originalThe author argues the schedule is an underappreciated structural change that may alter the usefulness of existing signals and algorithms.
Thoughts on upcoming 23/5 trading? (starting 12/06/2026) [https://www.nasdaq.com/newsroom/nasdaq-explains-what-is-23-5-trading](https://www.nasdaq.com/newsroom/nasdaq-explains-what-is-23-5-trading) I asked some AI garbage and there are supposedly 30-40 million individual
The author sees the change favoring large trading firms over individual traders.
Watch Trading activity in the extended session after December 6.
Open originalThe author cites the recent successful Starship flight as a long-term catalyst.
SpaceX historic Flight 15, will the December unlock really trigger a selloff? Starship's first successful upper-stage catch.
The December unlock is the near-term supply risk the author is weighing.
Watch SpaceX trading around the December lockup expiration.
Open originalNo publications match your search.